Procysbi (cysteamine bitartrate) — Blue Cross Blue Shield of Montana
use supported by two peer-reviewed journal articles demonstrating safety and efficacy
Initial criteria
- The member resides in Ohio AND the plan is Fully Insured or HIM Shop (SG)
- The patient does NOT have any FDA labeled contraindications to the requested agent
- ONE of the following: A. The patient has another FDA labeled indication for the requested agent and route of administration OR B. The patient has another indication supported in compendia for the requested agent and route of administration OR C. The prescriber has submitted TWO articles from major peer-reviewed professional medical journals supporting the proposed use(s) as generally safe and effective (e.g., JAMA, NEJM, Lancet)
Approval duration
12 months